2De Liefde II,van der Klift M,de Laet CE,et al. Bone mineral density and fracture risk in type-2 diabetes meUitus : the Rotter-damstudy. Osteoporos Int ,2005,16 ( 12 ) : 1713-1720.
3Ohtori S,Akazawa T, Murata Y, et al. Risedronate decrease bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures[ J ], Clin N eurosei, 2010,17(2) :209-213.
4Gupta G Aronow WS. Treatment of postmenopausal osteopomsis. Compr Ther,2007,33 ( 3 ) : 114-119.
6Boonen S, Rizzoli R, Meunier PJ, et al. The need for clinical guidance in the use of calcium and vitamin D in the management of osteoporosis: a consensus report [ J ]. Osteopores Int,2004,15 (7):511 -514.
7Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteopomsis[J]. Calcif Tidd Int,1991,49:S9 - 13.
8Lewiecki EM. Treatment of osteoporosis with denosumab [ J ]. Maturitas, 2010, 66(2) : 182 - 186.
9Jupsin I, Collette J, Henrotin Y, et al. Strontium ranelate (Fujisawa/Servier) [J]. Curr Opin Investig Drugs, 2005,6 ( 4 ) : 435 - 444.
10Tascioglu F, Colak O, Armagan O, et al. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids : a comparison of alendronate and intranasal salmon calcitonin [ J ]. Rheumatol Int, 2005,26( 1 ) :21 -29.
